Mounjaro Dose for Weight Loss: A Guide to the Titration Schedule

If you've been prescribed Mounjaro — or are considering it — one of the first questions is usually about the dose. How much do you take? When does it go up? And how does the dose relate to weight loss? This guide walks through the standard titration schedule for tirzepatide and what the research shows at each step. It is educational only and not a substitute for guidance from a licensed prescriber.

What is Mounjaro and how is it dosed?

Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication. It activates two gut hormone receptors — GLP-1 and GIP — that help control blood sugar, slow stomach emptying, and reduce appetite [1][3]. Because it works on two pathways, it is sometimes called a dual GLP-1/GIP receptor agonist.

Tirzepatide is given as a subcutaneous injection (under the skin) once per week. Per the FDA label, the dose is increased gradually over several months. This step-up approach, called titration, gives your digestive system time to adjust and may lower the risk of side effects like nausea [1].

Is Mounjaro FDA-approved for weight loss?

No. Mounjaro itself is FDA-approved only for adults with type 2 diabetes [1]. In 2023, the FDA approved Zepbound — also tirzepatide, also made by Eli Lilly — for chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition [2].

Mounjaro vs. Zepbound: same medication, different indication

Mounjaro and Zepbound contain the same active drug (tirzepatide) at the same dose strengths. They differ in labeling, packaging, and the conditions they are approved to treat. The titration steps on the FDA labels are the same [1][2].

Mounjaro dosing schedule for weight loss

Per the FDA label, tirzepatide is titrated up slowly. The table below summarizes the schedule described in the label. It is shown for education only — your prescriber decides whether and when to make any changes based on your response and tolerability [1][2].

Starting dose: 2.5 mg

According to the label, 2.5 mg is a starter dose. It is not intended for long-term treatment or for weight loss on its own — its role is to help the body get used to the medication during the first month [1].

Titration steps: 5, 7.5, 10, 12.5, and 15 mg

After four weeks at 2.5 mg, the label moves to 5 mg. From there, the dose can be increased in 2.5 mg steps, with at least four weeks at each level before any further increase [1][2]. Whether to move up at all is a decision made with a prescriber.

How long to stay on each dose

The label specifies a minimum of four weeks between increases, but many people stay on a given dose longer. The right pacing depends on side effects, how appetite and weight are responding, and the prescriber's judgment [1].

Maintenance dose

The maintenance dose is the level that gives the best balance between results and tolerability for a given person. For some that may be 5 or 10 mg; for others it may be 15 mg. There is no single 'right' maintenance dose — it is individualized [1].

How to take Mounjaro

Injection technique and sites

Tirzepatide is injected under the skin (subcutaneously) into the abdomen, thigh, or upper arm. The FDA label recommends rotating injection sites with each dose [1]. Single-dose pens are used once and then discarded into a sharps container.

Day and time of week

Per the label, Mounjaro is taken on the same day each week, at any time of day, with or without food [1]. The day of the week can be changed if needed, as long as the last dose was given at least three days (72 hours) earlier.

What to do if you miss a dose

The FDA label states that a missed dose can be taken within four days (96 hours). If more than four days have passed, skip that dose and take the next one on the regular day. Two doses should not be taken close together [1]. If you are unsure, contact your prescriber or pharmacist.

How dose affects weight loss results

In general, higher maintenance doses of tirzepatide produced greater average weight loss in clinical trials. That said, the lower doses still produced meaningful weight loss, and many people do well without reaching the maximum dose [4].

Average weight loss by dose in clinical trials

SURMOUNT-1 was a 72-week trial of tirzepatide in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition, without type 2 diabetes. Participants also followed a reduced-calorie diet and increased physical activity [4].

When to increase or hold your Mounjaro dose

Tolerability and side effects

Dose increases are the most likely time for new or stronger side effects — most commonly nausea, diarrhea, constipation, or vomiting [1][4]. If these are significant, a prescriber may decide to keep you at the current dose longer, move up more slowly, or step down. Any change to your dose should be made with your prescriber.

Talking to your prescriber

A few things prescribers often consider before increasing the dose: how the current dose is being tolerated, the trend in weight and appetite, any new symptoms, and other medications you take. There is no clear benefit to rushing through titration — going slowly is often more comfortable and works well for many people [1].

Common side effects at each dose

The most common side effects reported in clinical trials of tirzepatide were gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. Most were mild to moderate and most often occurred during dose increases [1][4].

• Nausea — most common side effect, often improves over time
• Diarrhea or constipation
• Vomiting
• Decreased appetite (expected, but can affect hydration and nutrition)
• Indigestion or abdominal discomfort
• Injection site reactions
• Fatigue

Less common but serious risks listed in the label include pancreatitis, gallbladder problems, kidney injury related to dehydration from vomiting or diarrhea, and severe allergic reactions [1]. Seek medical care for severe abdominal pain, persistent vomiting, signs of dehydration, or symptoms of a serious allergic reaction.

Who should not take Mounjaro

Per the FDA label, tirzepatide is not appropriate for people with [1][2]:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• A known serious allergy to tirzepatide or any of its ingredients
• Pregnancy (tirzepatide is not recommended during pregnancy)

Extra caution and prescriber oversight are also needed for people with a history of pancreatitis, severe gastrointestinal disease (such as gastroparesis), diabetic retinopathy, or kidney disease, and for those taking insulin or sulfonylureas (because of low blood sugar risk) [1]. A licensed prescriber can review your full history and decide whether tirzepatide is a safe option.

Frequently asked questions

Editorial note: This article was written with AI assistance and reviewed by a human editor for accuracy and adherence to current FDA labeling. It is educational content, not medical advice.

Keep reading

GLP-1 Medications

Semaglutide for Weight Loss: How It Works, Results, and Who Qualifies

GLP-1 Basics

Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound: The 2026 GLP-1 comparison

GLP-1 Weight Loss

Semaglutide Dose for Weight Loss: A Step-by-Step Guide